Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
04/27/2011 | CN102036665A Novel uses of sodium 4-phenylbutyrate (4 PBA) and the pharmaceutically acceptable salts thereof |
04/27/2011 | CN102036663A Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
04/27/2011 | CN102036660A Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
04/27/2011 | CN102030824A Monoclonal antibody of hepatitis B virus X protein and use thereof |
04/27/2011 | CN102028949A Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
04/27/2011 | CN102028948A Manganoporphyrin-alkylating agent combined medicine for treating tumors |
04/27/2011 | CN102028947A Inhibitor, inhibitor composition and inhibiting method of FAM3B gene, fatty liver treatment method and pharmaceutical application of inhibitor |
04/27/2011 | CN102028935A Method for forecasting, preventing and treating septicemia and septic shock and kit |
04/27/2011 | CN102028670A Composite capsule containing telmisartan and calcium ion channel antagonist |
04/27/2011 | CN102028645A Compositions comprising an nfkb-inhibitor and a non-retinoid collagen promoter |
04/27/2011 | CN101327190B Anti-tumor long-circulating target liposomes for injections |
04/26/2011 | US7932371 Tick octopamine receptor nucleic acid molecules |
04/26/2011 | US7932367 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
04/26/2011 | US7932363 Antibody that binds human eosinophil-derived basic protein |
04/26/2011 | US7932076 Compositions for culturing spirochetes |
04/26/2011 | US7931917 Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability |
04/26/2011 | CA2529538C Pyridoxamine for the treatment of diabetic kidney disease |
04/26/2011 | CA2479133C 2-4-diaminopyrimidine derivatives |
04/26/2011 | CA2477657C Cathepsin cysteine protease inhibitors |
04/26/2011 | CA2450728C Composition for the treatment of diseases which affect animals' hooves |
04/26/2011 | CA2446619C Permeation enhancers |
04/26/2011 | CA2446112C A method for regulating immune function in primates using the foxp3 protein |
04/26/2011 | CA2416572C Bispecific antibody for target cell-specific stimulation of the apo-1 cell surface receptor |
04/26/2011 | CA2408838C Drug/drug delivery systems for the prevention and treatment of vascular disease |
04/26/2011 | CA2402099C Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
04/26/2011 | CA2388656C Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
04/26/2011 | CA2371109C Improved pharmaceutical formulations |
04/26/2011 | CA2359945C Inhibitors of crystallization in a solid dispersion |
04/26/2011 | CA2337988C Inhibitors of proteasomal activity for stimulating bone and hair growth |
04/26/2011 | CA2326141C Use of receptor of a ror family for screening substances useful for the treatment of atherosclerosis |
04/26/2011 | CA2306024C Buccal, polar and non-polar spray or capsule |
04/26/2011 | CA2298934C Vectors derived from antibodies for transferring substances into cells |
04/21/2011 | WO2011047065A1 Recombinant human cc10 protein for treatment of influenza |
04/21/2011 | WO2011046811A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
04/21/2011 | WO2011046160A1 Method for screening of substance capable of preventing virus infection, and agent for preventing virus infection |
04/21/2011 | WO2011045075A1 Compositions comprising tramadol and celecoxib in the treatment of pain |
04/21/2011 | WO2011045068A2 Pharmaceutical composition containing cannabinoid-receptor antagonists |
04/21/2011 | US20110092674 Non-Functional P2X7 Receptor |
04/21/2011 | US20110092528 Piperidinyl compounds that selectively bind integrins |
04/21/2011 | US20110092523 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
04/21/2011 | US20110092482 Methods and compositions |
04/21/2011 | US20110092471 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
04/21/2011 | US20110092442 Anticancer agent containing bl-angiostatin |
04/21/2011 | US20110091920 METHOD OF DIAGNOSING A CLINICAL CONDITION BY DETECTION OF A PAPP-A/proMBP COMPLEX |
04/21/2011 | US20110091892 Methods for the Diagnosis and Treatment of Lung Cancer |
04/21/2011 | US20110091876 Zcytor19 polynucleotides, polypeptides, antibodies and methods of use |
04/21/2011 | US20110091578 Method of stimulating tissue healing |
04/21/2011 | US20110091556 Antimicrobial compositions and methods of use |
04/21/2011 | US20110091541 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
04/21/2011 | US20110091516 Muscle-based grafts/implants |
04/21/2011 | US20110091472 Compositions for treating psoriasis |
04/21/2011 | US20110091413 Therapeutic use of interleukin-2 mutants |
04/21/2011 | US20110091406 Composition and method for protecting labile active components during high temperature drying |
04/21/2011 | US20110091379 Method for treating tumors and their metastases |
04/21/2011 | DE202009017772U1 Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid Combination products with cytokine antagonist and corticosteroid |
04/21/2011 | CA2777560A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
04/20/2011 | EP2312482A1 Systems and methods for providing a stem cell bank |
04/20/2011 | EP2311980A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
04/20/2011 | EP2311979A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
04/20/2011 | EP2311978A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
04/20/2011 | EP2311960A2 Bv8 nucleic acids and polypeptides with mitogenic activity |
04/20/2011 | EP2311953A1 Bone/joint disease susceptibility gene and use thereof |
04/20/2011 | EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
04/20/2011 | EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
04/20/2011 | EP2311882A1 Reducing the immunogenicity of fusion proteins |
04/20/2011 | EP2311875A1 Treatment with anti-VEGF antibodies |
04/20/2011 | EP2311869A1 Use of mammalian cytokine; related reagents |
04/20/2011 | EP2311862A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311861A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311860A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311852A1 Anti-infarction molecules |
04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |
04/20/2011 | EP2311497A1 Use of oligouronates |
04/20/2011 | EP2311496A1 A combination of morphine and oxycodone for use in the alleviation or prevention of pain |
04/20/2011 | EP2311495A1 Vascularization inhibitors |
04/20/2011 | EP2311494A1 Histone modification inhibitor specific to target gene |
04/20/2011 | EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment |
04/20/2011 | EP2311465A1 Remedies for diseases to be applied to eye |
04/20/2011 | EP2311461A1 Methods for treating cancer by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines |
04/20/2011 | EP2311453A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
04/20/2011 | EP2311452A1 Topical composition comprising n-acetyl glucosamine |
04/20/2011 | EP2311449A1 Orally administrated food supplement comprising carnitine |
04/20/2011 | EP2311446A1 Compositions comprising Tramadol and Celecoxib in the treatment of pain |
04/20/2011 | EP2311443A1 Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
04/20/2011 | EP2311441A1 Dosage formulations for acetylcholinesterase inhibitors |
04/20/2011 | EP2310052A2 Acne treatment compositions comprising nanosilver and uses |
04/20/2011 | EP2310051A1 Combination of a parp inhibitor and an akt kinase activating compound |
04/20/2011 | EP2310050A1 Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
04/20/2011 | EP2310039A1 Fgf-9 and its use relating to blood vessels |
04/20/2011 | EP2310007A2 Improving renal function with quercetin-containing compositions |
04/20/2011 | EP2310006A2 Treating cancer |
04/20/2011 | EP2310005A2 Treatment of inflammatory conditions with isothiocyanates |
04/20/2011 | EP2061444B1 Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
04/20/2011 | EP1859793B1 Novel combinational use of a sulfonamide compound in the treatment of cancer |
04/20/2011 | EP1569657B1 Use of amphiphilic lipids for the preparation of a pharmaceutical composition for reducing tumor metastasis |
04/20/2011 | EP1505963B1 Hepatitis c virus inhibitors |
04/20/2011 | EP1392319B1 Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same |
04/20/2011 | EP1385993B1 Method of detecting and treating tuberous sclerosis complex associated disorders |
04/20/2011 | EP1224461B1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
04/20/2011 | EP1082415B1 Methods useful for modulation of angiogenesis using tyrosine kinase src |